Lymphotoxin-alpha deficiency completely protects C57BL/6 mice from developing clinical experimental autoimmune myasthenia gravis
E Goluszko, P Hjelmström, C Deng, MA Poussin… - Journal of …, 2001 - Elsevier
A complete prevention of clinical experimental autoimmune myasthenia gravis (EAMG) was
observed in lymphotoxin (LT)-α deficient (LT-α−/−) mice compared to LT-α+/+ mice when
immunized with acetylcholine receptor. However, only a partial prevention of clinical EAMG
incidence was observed in LT-β−/− mice compared to LT-β+/+ mice. LT-α−/− and LT-β−/−
mice had lower mean titers of total IgG, IgG1, IgG2a and IgG2b and higher or equal mean
titers of IgM anti-AChR antibodies compared to controls. Therefore, LT-α−/− and LT-β …
observed in lymphotoxin (LT)-α deficient (LT-α−/−) mice compared to LT-α+/+ mice when
immunized with acetylcholine receptor. However, only a partial prevention of clinical EAMG
incidence was observed in LT-β−/− mice compared to LT-β+/+ mice. LT-α−/− and LT-β−/−
mice had lower mean titers of total IgG, IgG1, IgG2a and IgG2b and higher or equal mean
titers of IgM anti-AChR antibodies compared to controls. Therefore, LT-α−/− and LT-β …
